[{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"ImmuneOncia Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"IMC-002","moa":"CD20\/CD47","graph1":"Oncology","graph2":"Phase I","graph3":"3D Medicines Corporation","amount2":0.46999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.46999999999999997,"dosageForm":"Infusion","sponsorNew":"3D Medicines Corporation \/ 3D Medicines Corporation","highestDevelopmentStatusID":"6","companyTruncated":"3D Medicines Corporation \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Y-Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Envafolimab","moa":"||CD3\/PDL1","graph1":"Oncology","graph2":"Preclinical","graph3":"3D Medicines Corporation","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"3D Medicines Corporation \/ 3D Medicines Corporation","highestDevelopmentStatusID":"4","companyTruncated":"3D Medicines Corporation \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"3D185","moa":"FGFR","graph1":"Oncology","graph2":"Phase I","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"3D185","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Aravive","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase III","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"3D Medicines Corporation \/ 3D Medicines Corporation","highestDevelopmentStatusID":"10","companyTruncated":"3D Medicines Corporation \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Envafolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Envafolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Envafolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Envafolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Envafolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Envafolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Envafolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Envafolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Envafolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Envafolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"3D011-08","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"3D1002","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"3D189","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"3D229","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"3D Medicines Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"3D Medicines Corporation \/ Undisclosed"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"3D Medicines Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Anlotinib Hydrochloride","moa":"Platelet-derived growth factor receptor beta | Vascular endothelial growth factor receptor 2 | Vascular endothelial growth factor receptor 3 | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"3D Medicines Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3D Medicines Corporation \/ 3D Medicines Corporation","highestDevelopmentStatusID":"1","companyTruncated":"3D Medicines Corporation \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Sellas Life Sciences Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"Galinpepimut-S","moa":"||Wilms tumor protein","graph1":"Oncology","graph2":"Phase III","graph3":"3D Medicines Corporation","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"3D Medicines Corporation \/ 3D Medicines Corporation","highestDevelopmentStatusID":"10","companyTruncated":"3D Medicines Corporation \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"3D Medicines Corporation","sponsor":"Sellas Life Sciences Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Galinpepimut-S","moa":"Wilms tumor protein","graph1":"Oncology","graph2":"Phase III","graph3":"3D Medicines Corporation","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"3D Medicines Corporation \/ 3D Medicines Corporation","highestDevelopmentStatusID":"10","companyTruncated":"3D Medicines Corporation \/ 3D Medicines Corporation"}]
Find Clinical Drug Pipeline Developments & Deals by 3D Medicines Corporation
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
